Study of Adaptive Radiotherapy Boost for Prostate and Bladder Cancers Using MR-Linac Technology to Improve Safety and Effectiveness

What this Trial Is About

Researchers are evaluating if adaptive radiation boost can effectively treat genitourinary cancers, specifically prostate cancer patients with local relapse after prostate removal and bladder cancer patients undergoing bladder-conserving treatment. The study aims to determine whether adaptive boost reduces toxic side effects while maintaining or improving treatment effectiveness. This trial is sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Participants will receive adaptive radiation therapy using a 1.5-Tesla MR-Linac machine. Prostate cancer patients post-prostatectomy will receive specific radiation doses targeting the prostate bed and boost areas, while bladder cancer patients will receive targeted doses to the bladder tumor and surrounding tissues. Treatment visits occur once every two weeks during radiation therapy. Throughout the study, participants will attend clinic visits every two weeks during treatment and every three months afterward. They will complete regular quality-of-life questionnaires focusing on genitourinary, gastrointestinal, and sexual health. The study will monitor acute urinary and gastrointestinal toxicities three months after treatment and track long-term outcomes such as disease control, survival, late toxicities, and quality of life for up to two years.

Adaptive Radiotherapy for Genitourinary Cancers